Novartis NVS announced that the FDA has approved Fabhalta (iptacopan) for a third indication. The regulatory body approved the drug for the treatment of adults with C3 glomerulopathy (C3G) to ...

The approval Vanrafia marks the third drug approval for Novartis in its renal disease portfolio. Shares of Novartis have risen 16.5% year to date compared with the large cap pharmaceutical ...

In early April, Novartis drug Vanrafia won accelerated FDA approval as ... becoming the first FDA-approved treatment for C3 glomerulopathy, an ultra-rare kidney disease that can progress to ...

Novartis has claimed accelerated approval from the FDA for Vanrafia ... the treatment of rare kidney disease IgA nephropathy (IgAN). Vanrafia (atrasentan) is the first drug in the selective ...

Novartis to buy Regulus for $0.8 billion upfront with potential for $1.7B total based on ADPKD drug milestone; deal set to ...

Novartis has committed another $1.7 billion to its ambition to become a kidney disease leader. The Swiss drugmaker is making ...

(Reuters) -Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion, giving the Swiss drugmaker access to an experimental drug to treat a life-threatening kidney disease. Under the ...

EAST HANOVER, N.J., March 20, 2025 /PRNewswire/ -- Novartis today announced that oral Fabhalta (iptacopan) has received U.S. Food and Drug Administration (FDA) approval for the treatment of ...

On Thursday, the U.S. Food and Drug Administration (FDA) approved Novartis AG’s ... This is the third US approval for Fabhalta and its second within the Novartis kidney disease portfolio since August ...

Shares of Regulus more than doubled to $7.8. The deal, expected to bolster Novartis' lineup of kidney disease drugs ... the only treatment approved by the U.S. Food and Drug Administration in ...